There are no key questions, per se, for which to write conclusions, beyond what is summarized as needed in the rationale for the recommendations. Gaps in the evidence are discussed as needed to support the recommendations. 2 There is a public comment period for the guideline as a whole, not for the systematic review, per se. 3 The guideline is published in a manner that ensures free public access; however, there is no stand-alone systematic review published. IOM Standards for Developing Trustworthy Clinical Practice Guidelines Part of KDIGO Process? 1. Establishing Transparency 1.1 The processes by which a CPG is developed and funded should be detailed explicitly and publicly accessible. Yes 2. Management of Conflict of Interest (COI) Yes 2.1 Prior to selection of the guideline development group (GDG), individuals being considered for membership should declare all interests and activities potentially resulting in COI with development group activity, by written disclosure to those convening the GDG: Yes Disclosure should reflect all current and planned commercial (including services from which a clinician derives a substantial proportion of income), non-commercial, intellectual, institutional, and patient public activities pertinent to the potential scope of the CPG. Yes (not intellectual) 2.2 Disclosure of COIs within GDG: All COI of each GDG member should be reported and discussed by the prospective development group prior to the onset of his or her work. Reported, not discussed Each panel member should explain how his or her COI could influence the CPG development process or specific recommendations. No Members of the GDG should divest themselves of financial investments they or their family members have in, and not participate in marketing activities or advisory boards of, entities whose interests could be affected by CPG recommendations. Not explicitly Whenever possible GDG members should not have COI. 